TP53 and ovarian carcinoma: Moreover, d16 can inhibit HR and synergize with PARPis in several BRCA-proficient ovarian and breast cancer cells, providing a new therapeutic strategy for the treatment of TP53-mutated, BRCA1/2-WT (wild-type), breast and ovarian cancers.